Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma

New Drug: Glofitamab-gxbm for selected relapsed or refractory large B-cell lymphomas

2023-06-07

  • Study

    Phase I-II, open-label, multicenter study
    Relapse or refractory large cell lymphoma
    Glofitamab (n=132)

  • Efficacy

    cORR: 56% [74 of 132 pts]
    CR: 43% [ 56 of 132 pts]
    mDoR: 18.4 mos [11.4-NR]

  • Safety

    Grade≥3: CRS (4.3%), ICANS (4.8%)


    • https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf

    Reviewed by Elvin CHALABİYEV, MD on AUG 10, 2023